Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
SenesTech, Inc. filed an amended report to add a missing conformed signature, and confirmed that President and Chief Executive Officer Joel L. Fruendt has notified the company he will retire from both his executive role and the Board.
His retirement will be effective on the earlier of June 30, 2026, or the appointment of a successor CEO. Under a separation agreement, he will receive continued base salary through December 15, 2026, company-paid or reimbursed health insurance premiums through December 31, 2026, and accelerated vesting of his stock options, subject to his release of claims. The Board appointed Jamie Bechtel as Interim Executive Chair, with annual compensation of $247,500 for that role in addition to existing Board-related pay.
SenesTech, Inc. announced that President and Chief Executive Officer Joel L. Fruendt plans to retire from the company and its Board, effective on the earlier of June 30, 2026 or the appointment of a successor CEO. The company and Mr. Fruendt entered into a separation agreement that provides continued base salary through December 15, 2026, health insurance premiums paid or reimbursed through December 31, 2026, and accelerated vesting of his stock options, subject to his signing a release of claims.
The Board appointed Jamie Bechtel as Interim Executive Chair on January 26, 2026. She will receive $247,500 per year for this role, in addition to any existing compensation for her service on the Board and its committees.
SenesTech, Inc. (SNES) reported a small insider transaction by a director. On 11/18/2025, the director sold 62 shares of common stock at a price of $2.71 per share, and reported owning 0 shares beneficially after this transaction. The filing notes that the share amounts have been adjusted to reflect a 1-for-20 reverse stock split on November 15, 2022, a 1-for-12 reverse stock split on November 14, 2023, and a 1-for-10 reverse stock split on July 11, 2024.
SenesTech, Inc. (SNES) reported an insider transaction on Form 4. A director of the company sold 1 share of common stock on 11/14/2025 at a price of $2.75 per share. Following this transaction, the reporting person held 0 shares of SenesTech common stock in direct ownership. The filing is signed by /s/ Thomas C. Chesterman, Attorney-in-Fact on 11/17/2025.
SenesTech (SNES) appointed Michael Edell as Interim Chief Operating Officer and outlined his compensation terms. The role is effective November 3, 2025, with an employment offer letter executed on November 7, 2025.
Edell will receive $30,000 per month and may earn bonuses of up to $25,000 for Q4 2025 and up to $30,000 for Q1 2026, subject to Board discretion. The agreement runs for six months on an at‑will basis. Either party may terminate with 60 days’ notice; the company can immediately relieve duties while continuing salary during the notice period. No additional compensation or benefits are provided unless authorized in writing, apart from requirements under California law, and Edell is restricted from competing during employment.
SenesTech (SNES) filed its Q3 2025 report, highlighting improved growth and liquidity. Revenue reached $690,000, up 43% year over year, driven largely by the Evolve product line, while ContraPest declined. Gross profit was $433,000 with a 62.8% margin in the quarter; for the first nine months, revenue was $1.8 million with a 64.2% gross margin. Net loss narrowed to $1.3 million for the quarter.
Management reports that prior substantial doubt about continuing as a going concern has been alleviated. During 2025, financing transactions generated $13.2 million in net proceeds, and cash, cash equivalents and short‑term investments totaled $10.2 million as of September 30, 2025, supporting at least the next 12 months. The company ended the period with 5,223,015 shares outstanding as of November 7, 2025. Operating cash use improved versus last year, and higher interest income reflected larger average balances.
Evolve Rat and Evolve Mouse now comprise the majority of sales across e‑commerce, professional, and retail channels. Operating expenses were stable year over year as cost containment offset higher legal and franchise fees. An at‑the‑market program added $2.7 million year to date, and warrant exercises added $10.5 million, bolstering liquidity while the company works toward higher‑margin growth.
SenesTech (SNES) filed its Q3 2025 report, highlighting improved growth and liquidity. Revenue reached $690,000, up 43% year over year, driven largely by the Evolve product line, while ContraPest declined. Gross profit was $433,000 with a 62.8% margin in the quarter; for the first nine months, revenue was $1.8 million with a 64.2% gross margin. Net loss narrowed to $1.3 million for the quarter.
Management reports that prior substantial doubt about continuing as a going concern has been alleviated. During 2025, financing transactions generated $13.2 million in net proceeds, and cash, cash equivalents and short‑term investments totaled $10.2 million as of September 30, 2025, supporting at least the next 12 months. The company ended the period with 5,223,015 shares outstanding as of November 7, 2025. Operating cash use improved versus last year, and higher interest income reflected larger average balances.
Evolve Rat and Evolve Mouse now comprise the majority of sales across e‑commerce, professional, and retail channels. Operating expenses were stable year over year as cost containment offset higher legal and franchise fees. An at‑the‑market program added $2.7 million year to date, and warrant exercises added $10.5 million, bolstering liquidity while the company works toward higher‑margin growth.
SenesTech (SNES) announced its third‑quarter results for the period ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1 to a Form 8‑K under Item 2.02.
The disclosure is presented as furnished, not filed, under the Exchange Act. The company also stated it has no obligation to publicly update forward‑looking statements. The text referenced in the report may be available on www.senestech.com.
SenesTech (SNES) announced its third‑quarter results for the period ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1 to a Form 8‑K under Item 2.02.
The disclosure is presented as furnished, not filed, under the Exchange Act. The company also stated it has no obligation to publicly update forward‑looking statements. The text referenced in the report may be available on www.senestech.com.
SenesTech (SNES) reported an insider ownership update via Form 3 for an officer serving as Interim Chief Operating Officer. The filing indicates no securities are beneficially owned (0) by the reporting person. The event date was 10/15/2025, and the form was filed by one reporting person.
The document was executed by Thomas C. Chesterman as attorney-in-fact.
SenesTech, Inc. (SNES) appointed Michael Edell as Interim Chief Operating Officer effective October 15, 2025. The company states there are no family relationships and no arrangements or understandings related to his election.
Edell will receive $30,000 per month and is eligible for a bonus at the Board’s discretion. Given the interim status, he will not receive standard benefits such as health insurance, retirement plans, paid time off, or other fringe benefits, and he will not be entitled to severance or other post‑termination compensation. He will be reimbursed for reasonable business expenses and will enter into the company’s standard indemnification agreement for officers.
SenesTech, Inc. filed an 8-K to report that it has filed a prospectus supplement registering an additional $7,580,675 of shares of its common stock under its existing at-the-market offering agreement with H.C. Wainwright & Co., LLC dated June 20, 2024. These shares may be issued from time to time through the sales agent under that agreement. The company states that, prior to this filing, it has already sold an aggregate of $3,048,894.72 of common stock through the same at-the-market program. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with its consent included as Exhibit 23.1.